UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adamantane - analogs & derivatives (626) 626
humans (569) 569
science & technology (503) 503
life sciences & biomedicine (487) 487
diabetes mellitus, type 2 - drug therapy (397) 397
male (378) 378
adamantane - therapeutic use (339) 339
female (329) 329
adamantane - adverse effects (302) 302
middle aged (268) 268
type 2 diabetes (243) 243
dipeptidyl-peptidase iv inhibitors - therapeutic use (223) 223
hypoglycemic agents - therapeutic use (221) 221
aged (200) 200
endocrinology & metabolism (193) 193
adamantane - administration & dosage (190) 190
treatment outcome (187) 187
adult (186) 186
pyrrolidines - therapeutic use (185) 185
nitriles - therapeutic use (182) 182
dipeptidyl-peptidase iv inhibitors - adverse effects (178) 178
hypoglycemic agents - adverse effects (175) 175
vildagliptin (169) 169
diabetes mellitus, type 2 - blood (153) 153
pyrrolidines - adverse effects (149) 149
diabetes (146) 146
nitriles - adverse effects (146) 146
pharmacology & pharmacy (146) 146
animals (145) 145
drug therapy, combination (142) 142
adamantane - pharmacology (140) 140
double-blind method (133) 133
dipeptides - adverse effects (127) 127
dipeptides - therapeutic use (126) 126
hypoglycemic agents - administration & dosage (111) 111
glycated hemoglobin a - metabolism (109) 109
saxagliptin (109) 109
biological and medical sciences (108) 108
medical sciences (105) 105
blood glucose - metabolism (104) 104
blood glucose - drug effects (99) 99
drug therapy (92) 92
metformin - therapeutic use (89) 89
care and treatment (87) 87
dipeptidyl-peptidase iv inhibitors - administration & dosage (87) 87
pyrrolidines - administration & dosage (87) 87
nitriles - administration & dosage (86) 86
glucose (83) 83
hypoglycemic agents (82) 82
adamantane - pharmacokinetics (75) 75
risk factors (72) 72
metformin (71) 71
clinical trials (69) 69
type 2 diabetes mellitus (69) 69
dipeptidyl-peptidase iv inhibitors - pharmacology (68) 68
endocrinopathies (68) 68
metformin - administration & dosage (68) 68
hypoglycemia - chemically induced (67) 67
sitagliptin phosphate (67) 67
diabetes. impaired glucose tolerance (66) 66
dosage and administration (66) 66
endocrine pancreas. apud cells (66) 66
general & internal medicine (66) 66
diabetes therapy (65) 65
analysis (63) 63
diabetes mellitus, type 2 - complications (63) 63
etiopathogenesis. screening. investigations. target tissue resistance (62) 62
internal medicine (62) 62
medicine, general & internal (62) 62
metformin - adverse effects (62) 62
dose-response relationship, drug (61) 61
dipeptides - administration & dosage (60) 60
research (60) 60
pyrrolidines - pharmacology (58) 58
young adult (58) 58
nitriles - pharmacology (57) 57
abridged index medicus (56) 56
adolescent (56) 56
dpp-4 inhibitor (56) 56
rats (56) 56
time factors (55) 55
administration, oral (53) 53
pyrazines - therapeutic use (52) 52
triazoles - therapeutic use (52) 52
pharmacology. drug treatments (48) 48
hypoglycemia (47) 47
medicine & public health (47) 47
diabetes mellitus (46) 46
glycosylated hemoglobin (45) 45
cardiovascular system & cardiology (44) 44
dextrose (44) 44
insulin (44) 44
glycated hemoglobin a - analysis (43) 43
hypoglycemic agents - pharmacology (43) 43
mice (43) 43
clinical trials as topic (42) 42
aged, 80 and over (41) 41
biomarkers - blood (41) 41
medicine, research & experimental (40) 40
research & experimental medicine (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (643) 643
Russian (16) 16
Japanese (7) 7
German (5) 5
Czech (3) 3
French (3) 3
Spanish (2) 2
Dutch (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American journal of clinical dermatology, ISSN 1175-0561, 06/2016, Volume 17, Issue 3, pp. 191 - 200
Life Sciences & Biomedicine | Dermatology | Science & Technology | Humans | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Thalidomide - analogs & derivatives | Isonicotinic Acids - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Pyrroles - administration & dosage | Adenosine - adverse effects | Adamantane - therapeutic use | Pyrroles - adverse effects | Adamantane - administration & dosage | Receptors, Lysosphingolipid - metabolism | Adamantane - analogs & derivatives | Isonicotinic Acids - adverse effects | Thalidomide - adverse effects | Biological Therapy | Isonicotinic Acids - therapeutic use | Piperidines - administration & dosage | Psoriasis - drug therapy | Adenosine A3 Receptor Antagonists - therapeutic use | Administration, Oral | Azetidines - adverse effects | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phosphodiesterase 4 Inhibitors - therapeutic use | Adenosine A3 Receptor Antagonists - adverse effects | Thalidomide - administration & dosage | Adenosine - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Azetidines - therapeutic use | Adenosine - analogs & derivatives | Thalidomide - therapeutic use | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Thiazoles - administration & dosage | Thiazoles - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | Phosphodiesterase 4 Inhibitors - administration & dosage | Adenosine - therapeutic use | Arthritis, Psoriatic - drug therapy | Pyrroles - therapeutic use | Adamantane - adverse effects | Adenosine A3 Receptor Antagonists - administration & dosage | Pyrimidines - administration & dosage | Clinical Trials as Topic | Niacinamide - administration & dosage | Biological Factors - therapeutic use | Janus Kinases - antagonists & inhibitors | Azetidines - administration & dosage | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents | Index Medicus | Abridged Index Medicus
Journal Article
Pharmacology, ISSN 0031-7012, 08/2010, Volume 86, Issue 1, pp. 44 - 57
Review | Glycemic control | Diabetes | Incretin mimetics | Hypoglycemia | Dipeptyl peptidase type 4 inhibitor | Weight | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Triazoles - adverse effects | Nitriles - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Pyrrolidines - adverse effects | Pyrazines - therapeutic use | Weight Loss - drug effects | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Adult | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glucagon-Like Peptide 1 - pharmacology | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Triazoles - pharmacology | Pyrazines - adverse effects | Venoms - therapeutic use | Venoms - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Nitriles - adverse effects | Pyrazines - pharmacology | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Nitriles - therapeutic use | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2017, Issue 2, pp. CD009966 - CD009966
Glomerular diseases | Adamantane | Dipeptidyl Peptidase 4 | Dipeptidyl‐Peptidase IV Inhibitors | Hypoglycemic Agents | Glycated Hemoglobin A | Child health | Glomerular disease | Pyrrolidines | Diabetes Mellitus, Type 1 | Nitriles | Diabetes Mellitus, Type 2 | Sitagliptin Phosphate | Diabetic kidney disease | Kidney disease | Fasting | Pharmacological interventions | Pioglitazone | Graft Survival | Kidney Transplantation | Chronic kidney disease | Hypoglycemia | Insulin | Randomized Controlled Trials as Topic | Vildagliptin | Medicine General & Introductory Medical Sciences | Thiazolidinediones | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Pyrrolidines - adverse effects | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Fasting - blood | Adamantane - therapeutic use | Hypoglycemia - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Thiazolidinediones - adverse effects | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 1 - blood | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Graft Survival - drug effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects | Index Medicus
Journal Article
Journal Article
Diabetes care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
Journal Article
Metabolism, clinical and experimental, ISSN 0026-0495, 2014, Volume 63, Issue 7, pp. 957 - 967
Endocrinology & Metabolism | Glimepiride | Insulin resistance | Vildagliptin | Type 2 diabetes mellitus | Oral fat load | Life Sciences & Biomedicine | Science & Technology | Fundamental and applied biological sciences. Psychology | Feeding. Feeding behavior | Diabetes. Impaired glucose tolerance | Vertebrates: anatomy and physiology, studies on body, several organs or systems | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Pyrrolidines - adverse effects | Male | Weight Loss - drug effects | Metformin - adverse effects | Pyrrolidines - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Postprandial Period | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypolipidemic Agents - adverse effects | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Insulin Resistance | Sulfonylurea Compounds - adverse effects | Hyperlipidemias - prevention & control | Diabetes Mellitus, Type 2 - blood | Intention to Treat Analysis | Aged | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use | Diabetics | Care and treatment | Diabetes | Comparative analysis | Index Medicus
Journal Article